Leonard B. Seeff

Leonard B. Seeff's AcademicInfluence.com Rankings

Leonard B. Seeff

Philosophy

#4986

World Rank

#7681

Historical Rank

Logic

#2338

World Rank

#3312

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Leonard B. Seeff's Degrees

Doctorate Medicine Harvard University

Why Is Leonard B. Seeff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Leonard B. Seeff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis, management, and treatment of hepatitis C: An update (2009) (3138)
Diagnosis, management, and treatment of hepatitis C (2004) (1812)
A report of a case and review of the literature (1976) (1753)
Natural history of hepatitis C. (1999) (1639)
Natural history of chronic hepatitis C (2002) (1608)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011) (1152)
National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C (1997) (1042)
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. (2000) (770)
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. (1977) (688)
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis (1992) (646)
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. (1981) (600)
Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. (2000) (548)
Peginterferon and ribavirin for chronic hepatitis C. (2006) (501)
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. (2009) (484)
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 (2002) (474)
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. (1978) (444)
Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring (2000) (394)
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. (2010) (389)
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. (1976) (367)
Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. (1986) (364)
Hepatitis C and renal disease: an update. (2003) (357)
45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults (2000) (351)
Long‐term mortality and morbidity of transfusion‐associated non‐A, non‐B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study (2001) (332)
Liver injury from herbals and dietary supplements in the U.S. Drug‐Induced Liver Injury Network (2014) (307)
TRANSMISSION OF NON-A, NON-B HEPATITIS FROM MAN TO CHIMPANZEE (1978) (297)
Causality assessment in drug‐induced liver injury using a structured expert opinion process: Comparison to the Roussel‐Uclaf causality assessment method (2010) (289)
Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop (2010) (288)
National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 (2002) (286)
Drug‐induced liver injury: Summary of a single topic clinical research conference (2006) (280)
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. (1978) (275)
National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: 2002 June 10-12, 2002 (2003) (274)
Complementary and alternative medicine in chronic liver disease (2001) (270)
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. (2000) (268)
The history of the “natural history” of hepatitis C (1968–2009) (2009) (248)
Natural history of hepatitis C (1997) (235)
Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients (1989) (234)
Liver injury from herbal and dietary supplements (2017) (219)
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. (1987) (212)
The Relationship of Acute Transfusion-Associated Hepatitis to the Development of Cirrhosis in the Presence of Alcohol Abuse (2001) (208)
Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance (1991) (190)
Natural history of hepatitis C. (2005) (180)
Use of complementary and alternative medicine in patients with liver disease (2002) (175)
A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. (1977) (174)
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial (2006) (172)
National institutes of health consensus development conference: Management of hepatitis C: 2002 (2002) (168)
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (2011) (163)
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury (2008) (162)
Management and Treatment of Hepatitis C (2004) (162)
Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial (2007) (148)
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. (1992) (139)
Histopathologic analysis of suspected amiodarone hepatotoxicity. (1990) (135)
Hepatotoxicity Due to Hydroxycut: A Case Series (2010) (124)
A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. (2020) (123)
Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C (2012) (119)
Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation (2007) (118)
A Framework for Management of Hepatitis C in Prisons (2006) (109)
Telithromycin‐associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases (2009) (106)
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. (2003) (105)
Jaundice Due to Bacterial Infection (1979) (104)
Natural history of chronic hepatitis C (2002) (102)
National Academy of Clinical Biochemistry Standards of Laboratory Practice : Laboratory Guidelines for Screening , Diagnosis and Monitoring of Hepatic Injury (2001) (97)
Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care (2004) (96)
Testing for Hepatitis C Virus Infection Should Be Routine for Persons at Increased Risk for Infection (2004) (94)
National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 (2002) (93)
Herbal products and the liver: a review of adverse effects and mechanisms. (2015) (92)
Global Burden of Disease (GBD) for Hepatitis C The Global Burden of Hepatitis C Working Group (2004) (88)
Immunoprophylaxis of viral hepatitis. (1979) (87)
Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. (2003) (85)
Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period. (1980) (82)
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States (2016) (80)
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts (2020) (78)
Va cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. (1975) (78)
Apparent potentiation of acetaminophen hepatotoxicity by alcohol. (1980) (76)
Treatment of chronic active hepatitis. An analysis of three controlled trials. (1977) (73)
Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial (2011) (72)
Introduction: The burden of hepatocellular carcinoma. (2004) (68)
Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. (1986) (67)
Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. (2004) (66)
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10‐12, 2002 (2002) (66)
Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. (2001) (62)
Guidelines for detection of hepatotoxicity due to drugs and chemicals (1980) (62)
The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy (2007) (60)
Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. (1981) (60)
Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119) (1991) (59)
Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veterans Administration cooperative study of needle-stick hepatitis. The Veterans Administration Cooperative Study Group. (1979) (58)
Hepatitis C from a needlestick injury. (1991) (57)
Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 (2004) (57)
Viral hepatitis, A though E, complicating pregnancy. (1992) (57)
AASLD PRACTICE GUIDELINE Diagnosis, Management, and Treatment of Hepatitis C (2004) (57)
The natural history of chronic hepatitis C infection. (1996) (56)
Allopurinol hepatotoxicity. Report of two cases and review of the literature. (1981) (56)
Hepatic disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study. (1975) (48)
EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE Preliminary Report of the Veterans Administration Cooperative Study (1975) (48)
The natural history of hepatitis C—A quandary (1998) (48)
Causality Assessment for Suspected DILI During Clinical Phases of Drug Development (2014) (46)
Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. (1995) (45)
High-density lipoproteins from human alcoholics exhibit impaired reverse cholesterol transport function. (2000) (43)
A brief history of the treatment of viral hepatitis C (2012) (42)
Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. (2000) (40)
Jaundice due to bacterial infection. (1979) (40)
Antibody to human retroviruses among drug users in three east coast American cities, 1972-1976. (1991) (36)
Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome. (1984) (36)
Hepatitis C: State of the Art at the Millennium (2001) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
Acute non-A, non-B hepatitis. Prolonged presence of the infectious agent in blood. (1979) (35)
Complementary and alternative Medicine (CAM) for the Treatment of Chronic Hepatitis B and C: A Review (2006) (35)
The natural history of chronic hepatitis C virus infection. (1997) (35)
Liver injury induced by herbal complementary and alternative medicine. (2013) (34)
Mortality follow‐up of the 1942 epidemic of hepatitis B in the U.S. Army (1993) (34)
Predicting clinical outcomes using baseline and follow‐up laboratory data from the hepatitis C long‐term treatment against cirrhosis trial (2011) (33)
Transfusion-associated non-A, non-B hepatitis (1988) (33)
Natural history of viral hepatitis, type C. (1995) (32)
Effect of chlorpromazine on the function of the perfused isolated liver. (1971) (32)
Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: Divergence over time (2001) (31)
Herbal hepatotoxicity. (2007) (31)
Current Perspectives in Hepatology (2012) (30)
Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors (2019) (30)
Acquired immunity to human non-A, non-B hepatitis: cross-challenge of chimpanzees with three infectious human sera. (1979) (29)
Stability of aspartate aminotransferase and alanine aminotransferase activities. (1983) (28)
Why is there such difficulty in defining the natural history of hepatitis C? (2000) (27)
Quinidine hepatotoxicity. A report of a case and review of the literature. (1976) (27)
Transmission of human non‐a, non‐b hepatitis to chimpanzees following failure to transmit gb agent hepatitis (1980) (27)
HLA‐B*35:01 and Green Tea–Induced Liver Injury (2020) (26)
Spousal Transmission of the Hepatitis C Virus? (1994) (24)
The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled (2019) (23)
Lack of Transmission of Type B Hepatitis by Fiberoptic Upper Endoscopy (1980) (23)
Lack of susceptibility of marmosets to human non-A, non-B hepatitis. (1979) (23)
Hepatitis C: a brief clinical overview. (2001) (22)
Evolutionary analysis of hepatitis C virus gene sequences from 1953 (2013) (20)
Diagnostic Tests for Hepatitis C: Where Are We Now? (1995) (19)
Chronic hepatitis in hemophilia. (1977) (19)
Antibody to the Hepatitis B Virus- Associated Delta-Agent in Immune Serum Globulins (1984) (19)
Are herbals as safe as their advocates believe? (2009) (19)
Natural history of chronic type B hepatitis. (1982) (19)
101 INCIDENCE RATES AND RISK FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE DUE TO HEPATITIS C: RESULTS OF THE HALT-C TRIAL (2008) (19)
Prevalence of hepatitis C virus associated cryoglobulinemia at a veterans hospital. (1997) (18)
Transfusion-associated hepatitis B: past and present. (1988) (17)
Hepatotoxicity of analgesics and anti-inflammatory agents. (1995) (16)
Causes of increased plasma creatine kinase activity after surgery. (1974) (16)
Hepatotoxicity of Herbals and Dietary Supplements (2013) (15)
Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. (2015) (14)
Serological diagnosis of acute viral hepatitis (1985) (14)
Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: Promises and limitations (1995) (14)
Viral hepatitis. (Clinical gastroenterology monograph series) (1979) (14)
Hepatitis in the drug abuser. (1975) (13)
Chapter 27 – Hepatotoxicity of Herbal Preparations (2006) (13)
167 Herbal and Dietary Supplement Induced Hepatotoxicity in the U.S. (2012) (12)
Drift in the hypervariable region of the hepatitis C virus during 27 years in two patients (2002) (12)
Management of untreated and nonresponder patients with chronic hepatitis C. (2010) (11)
Dilemma of the natural history of hepatitis C (1999) (11)
Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function. (1995) (11)
Is cirrhosis an inevitable consequence of chronic hepatitis C virus infection? (2005) (11)
Viral load as a predictor of progression of chronic hepatitis C? (2005) (11)
1364 DIAGNOSING HEPATOTOXICITY ATTRIBUTABLE TO HERBAL & DIETARY SUPPLEMENTS (HDS): TEST-RETEST RELIABILITY OF A NOVEL CAUSALITY ASSESSMENT TOOL (2012) (11)
Effect of thymosin immunostimulation with and without corticosteroid immunosuppression on chimpanzee hepatitis B carriers (1987) (10)
Drug-Induced Liver Injury Is a Major Risk for New Drugs (2015) (9)
Transfusion-associated non-A, non-B hepatitis. Where do we go from here? (1988) (9)
Measurement of lactate in ascitic fluid (1981) (8)
Passive and active immunoprophylaxis of hepatitis B. (1984) (8)
Should Donors with a History of Jaundice Still be Rejected (1981) (8)
Garcinia Cambogia, Either Alone or in Combination with Green Tea Causes Moderate to Severe Liver Injury. (2021) (7)
5 Natural history of hepatitis C (2000) (6)
Relationship between hepatic and pancreatic disease. (1976) (6)
Efforts to define the natural history of chronic hepatitis C continue. (2006) (6)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease (2009) (6)
Corticosteroid therapy for chronic active hepatitis. (1976) (6)
DRUG-INDUCED CHRONIC LIVER DISEASE (1998) (5)
Viral hepatitis. (Clinical gastroenterology monograph series): By Raymond S. Koff. 242 pp., $18.00. John Wiley & Sons, New York (1979) (5)
Hyman J. Zimmerman, MD (2000) (5)
Chapter 26 – Hepatotoxicity of Herbal Preparations (2012) (5)
Strategies for assessing the long-term consequences of Hepatitis C virus infection. (2000) (5)
Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts (2004) (5)
Hepatitis Infection in the Treatment of Opioid Dependence and Abuse (2008) (4)
The gold standard serologic marker for hepatitis B virus infectivity (1988) (4)
Antibody to the hepatitis B virus-associated delta-agent in immune serum globulins. (1984) (4)
TRANSMISSION OF AGENT OF POST-TRANSFUSION NON-A, NON-B HEPATITIS BY CRYOPRECIPITATE PREPARED FROM PLASMA OF SYMPTOMLESS CHRONIC CARRIER (1983) (4)
Histopathology of the liver in Down's syndrome (1967) (4)
In vitro immune responses to hepatitis B surface antigen (pre-S2 and S) following remote infection by hepatitis B virus in humans (1989) (3)
Corticosteroid therapy for chronic active hepatitis. (1976) (3)
More Severe Parenchymal Injury in Chronic Hepatitis C Acquired by Recent Injection Drug Use (2005) (3)
Immunization for viral hepatitis (1996) (3)
Hepatitis B: The virus, the disease, and the vaccine (1986) (3)
Current Perspectives In Hepatology Festschrift For Hyman J Zimmerman M D (1989) (3)
Immunoprophylaxis and treatment of viral hepatitis B. (1981) (2)
The Origins of the Modern‐Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman (2020) (2)
The American Association for the Study of Liver Diseases Presentation of the distinguished Achievement Award to (1987) (2)
Drug-Induced Liver Injury (2011) (2)
237 Progression of Advanced Chronic Hepatitis C (CHC): Further Follow-up Results From the Halt-C Trial (2010) (2)
Viral hepatitis: Laboratory and clinical science (1984) (2)
Afterword: HCV in the decades ahead. (2000) (2)
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence (2021) (2)
Jaundice of Systemic Infection (1989) (2)
Non‐A, non‐B hepatitis (1989) (2)
Therapy for chronic active hepatitis. (1984) (1)
HARVEY ALTER AND MICHAEL HOUGHTON: THE DISCOVERY OF HEPATITIS C AND THE INTRODUCTION OF SCREENING TO PREVENT ITS TRANSMISSION IN TRANSFUSED BLOOD (2014) (1)
Type B hepatitis after transfusion with blood positive for antibody to hepatitis B core antigen (Anti-HBc) (1978) (1)
Viral hepatitis: Biological and clinical features, specific diagnosis, and prophylaxis. By F. Blaine Hollinger, Joseph L. Melnick and William S. Robinson. 221 pp. New York: Raven Press, 1986. $29.50 (1986) (1)
Complementary and alternative medicines for hepatic disease. (2008) (1)
Invasive cervical cancer among women with aids in Europe and USA, 1994–1998 (2000) (1)
Non-A, non-B hepatitis: impact of the emergence of the hepatitis C virus. (1992) (1)
T1966 Patient Mortality and Liver Transplantation During the Halt-C Trial: Relationship to Chronic Liver Disease and Interferon Therapy (2010) (1)
Hepatitis B: The virus, the disease, and the vaccine: Edited by I. Millman, T. Eisenstein, and B. Blumberg. 252 pp., illustrated, $39.50. Plenum Press, New York, New York, 1984. ISBN 0-306-41723-5 (1986) (0)
Acetaminophen Hepatotoxicity in Alcoholics (2020) (0)
Reply: (2009) (0)
HCV carriers with persistently normal aminotransferase levels. Authors' reply (2004) (0)
Chronic active hepatitis (2005) (0)
Drug-induced liver disease: Edited by Geoffrey C. Farrell. 673 pp. $159.00. Churchill Livingstone Inc., New York, New York, 1994. ISBN 0-443-04368-X (1995) (0)
Reply to both letters: (2004) (0)
P17 Multicenter trials and cohort studies — valuable resources for long term studies of disease outcomes (1996) (0)
Guidelines for detection of hepatotoxicity due to drugs and chemicals: 143 pp., $6.50. U.S. Department of Health, Education & Welfare (NIH), Public Health Service, Bethesda, Maryland, 1979 (1980) (0)
Natural History , Treatment , and Prevention of Hepatitis C Moderator : (2000) (0)
New Hepatitis A Vaccines and Their Role in Prevention (1996) (0)
Viral hepatitis: Laboratory and clinical science: Edited by F. Deinhardt and J. Deinhardt. 585 pp., $89.75. Marcel Dekker, Inc., New York, New York, 1983 (1984) (0)
Mean Plasma Enzyme Activities before and after Surgery (2004) (0)
HCV carriers with persistently normal aminotransferase levels [2] (multiple letters) (2004) (0)
To the editor (0)
Infectivity of blood containing hepatitis-B antibody (1975) (0)
A prospective case controlled study of the prevalence of hepatitis C virus (HCV)-related cryoglobulinemia (CRYO) at an inner city hospital (1995) (0)
VA Collaborative Study of Liver Disease in Drug Addicts: Preliminary Report (1976) (0)
An Update on Treatment of Hepatitis C Virus Genotype 1 Infection and Viral Load Assessments To the (2012) (0)
Reply (2012) (0)
Erratum to New hepatitis A vaccines and their role in prevention (1996) (0)
Reply: (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Leonard B. Seeff?

Leonard B. Seeff is affiliated with the following schools:

Georgetown University